Total mortality · Men and non‐pregnant women ≥ 18 years old with essential hypertension
1 finding from 1 review
Serious adverse events · Men and non‐pregnant women ≥ 18 years old with essential hypertension
Phentermine/topiramate showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
All adverse events · Men and non‐pregnant women ≥ 18 years old with essential hypertension
Phentermine/topiramate may leads to higher all adverse events compared with placebo (low certainty).
1 finding from 1 review
Total mortality · Men and non‐pregnant women ≥ 18 years old with essential hypertension
Naltrexone/bupropion showed no clear difference in total mortality compared with placebo (moderate certainty).
1 finding from 1 review
Cardiovascular morbidity · Men and non‐pregnant women ≥ 18 years old with essential hypertension
Naltrexone/bupropion showed no clear difference in cardiovascular morbidity compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · Men and non‐pregnant women ≥ 18 years old with essential hypertension
Naltrexone/bupropion showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
All adverse events · Men and non‐pregnant women ≥ 18 years old with essential hypertension
Naltrexone/bupropion probably leads to higher all adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Cardiovascular morbidity · Men and non‐pregnant women ≥ 18 years old with essential hypertension
1 finding from 1 review
Serious adverse events · Men and non‐pregnant women ≥ 18 years old with essential hypertension
Orlistat probably leads to higher serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
All adverse events · Men and non‐pregnant women ≥ 18 years old with essential hypertension
It is very uncertain whether orlistat changes all adverse events compared with placebo (very low certainty).
1 finding from 1 review
Total mortality · Men and non‐pregnant women ≥ 18 years old with essential hypertension
1 finding from 1 review
Cardiovascular morbidity · Men and non‐pregnant women ≥ 18 years old with essential hypertension
1 finding from 1 review
Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase) · adults with trichotillomania
Antioxidants showed no clear difference in treatment responseaClinical Global Impressions ‐ Improvement Scale… compared with placebo (low certainty).
1 finding from 1 review
Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase) · adults with trichotillomania
Cell signal transducers showed no clear difference in treatment responseaClinical Global Impressions ‐ Improvement Scale… compared with placebo (low certainty).
1 finding from 1 review
Reduction of TTM symptom severityMassachusetts General Hospital Hair‐Pulling Scale (MGH‐HPS) · adults with trichotillomania
1 finding from 1 review
Withdrawals due to adverse events · adults with trichotillomania
1 finding from 1 review
Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase) · adults with trichotillomania
Glutamate modulators probably leads to higher treatment responseaClinical Global Impressions ‐ Improvement Scale… compared with placebo (moderate certainty).
1 finding from 1 review
Reduction of TTM symptom severityMassachusetts General Hospital Hair‐Pulling Scale (MGH‐HPS) · adults with trichotillomania
1 finding from 1 review
Withdrawals due to adverse events · adults with trichotillomania
1 finding from 1 review
Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase) · children and adolescents with trichotillomania
Glutamate modulators showed no clear difference in treatment responseaClinical Global Impressions ‐ Improvement Scale… compared with placebo (low certainty).
1 finding from 1 review